Drug Combination Details
| General Information of the Combination (ID: C91220) | |||||
|---|---|---|---|---|---|
| Name | Celastrol NP Info | + | TRAIL/Apo2L Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
|
Colon cancer
[ICD-11: 2B90]
|
Investigative | [1] | |||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | OVCAR-8 | CVCL_1629 | Ovarian serous adenocarcinoma | Homo sapiens | ||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| PLA-801D | CVCL_7110 | Lung giant cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Synergistic anticancer capabilities achieved by combining TRAIL/APO-2L and celastrol. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest. 2010 Jan;28(1):23-32. | |||
